schliessen

Filtern

 

Bibliotheken

Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data

WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible individuals by 2025. We have previously reported that use of these medicines is very low, but now aim to assess how such low use relates to their lack of availab... Full description

Journal Title: The Lancet 02 January 2016, Vol.387(10013), pp.61-69
Main Author: Khatib, Rasha
Other Authors: Mckee, Martin , Shannon, Harry , Chow, Clara , Rangarajan, Sumathy , Teo, Koon , Wei, Li , Mony, Prem , Mohan, Viswanathan , Gupta, Rajeev , Kumar, Rajesh , Vijayakumar, Krishnapillai , Lear, Scott A , Diaz, Rafael , Avezum, Alvaro , Lopez-Jaramillo, Patricio , Lanas, Fernando , Yusoff, Khalid , Ismail, Noorhassim , Kazmi, Khawar
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0140-6736 ; E-ISSN: 1474-547X ; DOI: 10.1016/S0140-6736(15)00469-9
Link: http://dx.doi.org/10.1016/S0140-6736(15)00469-9
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_S0140_6736_15_00469_9
title: Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data
format: Article
creator:
  • Khatib, Rasha
  • Mckee, Martin
  • Shannon, Harry
  • Chow, Clara
  • Rangarajan, Sumathy
  • Teo, Koon
  • Wei, Li
  • Mony, Prem
  • Mohan, Viswanathan
  • Gupta, Rajeev
  • Kumar, Rajesh
  • Vijayakumar, Krishnapillai
  • Lear, Scott A
  • Diaz, Rafael
  • Avezum, Alvaro
  • Lopez-Jaramillo, Patricio
  • Lanas, Fernando
  • Yusoff, Khalid
  • Ismail, Noorhassim
  • Kazmi, Khawar
subjects:
  • Medicine
ispartof: The Lancet, 02 January 2016, Vol.387(10013), pp.61-69
description: WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible individuals by 2025. We have previously reported that use of these medicines is very low, but now aim to assess how such low use relates to their lack of availability or poor affordability. We analysed information about availability and costs of cardiovascular disease medicines (aspirin, β blockers, angiotensin-converting enzyme inhibitors, and statins) in pharmacies gathered from 596 communities in 18 countries participating in the Prospective Urban Rural Epidemiology (PURE) study. Medicines were considered available if present at the pharmacy when surveyed, and affordable if their combined cost was less than 20% of household capacity-to-pay. We compared results from high-income, upper middle-income, lower middle-income, and low-income countries. Data from India were presented separately given its large, generic pharmaceutical...
language: eng
source:
identifier: ISSN: 0140-6736 ; E-ISSN: 1474-547X ; DOI: 10.1016/S0140-6736(15)00469-9
fulltext: fulltext
issn:
  • 0140-6736
  • 01406736
  • 1474-547X
  • 1474547X
url: Link


@attributes
ID1773371292
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_S0140_6736_15_00469_9
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_S0140_6736_15_00469_9
sourcesystemPC
dbid
0--K
1--M
2.FO
31B1
41P~
51RT
6457
74G.
87-5
99JM
10AABNK
11AAEDT
12AAKOC
13AAQFI
14ABBQC
15ABFNM
16ABLVK
17ABMZM
18ABYKQ
19ACIUM
20ACRLP
21AEKER
22AEVXI
23AFKWA
24AFTJW
25AFXIZ
26AGHFR
27AITUG
28AJBFU
29AJOXV
30AJRQY
31AJUYK
32AMFUW
33AMRAJ
34ANZVX
35BNPGV
36EO8
37EO9
38EP2
39EP3
40FDB
41FIRID
42FNPLU
43G-Q
44GBLVA
45J1W
46KOM
47OD.
48OO~
49P-8
50P-9
51PC.
52R2-
53RPZ
54SAD
55SDF
56SDG
57SEL
58SES
59SSH
60SSZ
61T5K
62UV1
63Z5R
pqid1760927783
galeid444450110
display
typearticle
titleAvailability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data
creatorKhatib, Rasha ; Mckee, Martin ; Shannon, Harry ; Chow, Clara ; Rangarajan, Sumathy ; Teo, Koon ; Wei, Li ; Mony, Prem ; Mohan, Viswanathan ; Gupta, Rajeev ; Kumar, Rajesh ; Vijayakumar, Krishnapillai ; Lear, Scott A ; Diaz, Rafael ; Avezum, Alvaro ; Lopez-Jaramillo, Patricio ; Lanas, Fernando ; Yusoff, Khalid ; Ismail, Noorhassim ; Kazmi, Khawar
contributorPure Study Investigators (Corporate Author)
ispartofThe Lancet, 02 January 2016, Vol.387(10013), pp.61-69
identifier
subjectMedicine
descriptionWHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible individuals by 2025. We have previously reported that use of these medicines is very low, but now aim to assess how such low use relates to their lack of availability or poor affordability. We analysed information about availability and costs of cardiovascular disease medicines (aspirin, β blockers, angiotensin-converting enzyme inhibitors, and statins) in pharmacies gathered from 596 communities in 18 countries participating in the Prospective Urban Rural Epidemiology (PURE) study. Medicines were considered available if present at the pharmacy when surveyed, and affordable if their combined cost was less than 20% of household capacity-to-pay. We compared results from high-income, upper middle-income, lower middle-income, and low-income countries. Data from India were presented separately given its large, generic pharmaceutical...
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://dx.doi.org/10.1016/S0140-6736(15)00469-9$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Khatib, Rasha
1Mckee, Martin
2Shannon, Harry
3Chow, Clara
4Rangarajan, Sumathy
5Teo, Koon
6Wei, Li
7Mony, Prem
8Mohan, Viswanathan
9Gupta, Rajeev
10Kumar, Rajesh
11Vijayakumar, Krishnapillai
12Lear, Scott A
13Diaz, Rafael
14Avezum, Alvaro
15Lopez-Jaramillo, Patricio
16Lanas, Fernando
17Yusoff, Khalid
18Ismail, Noorhassim
19Kazmi, Khawar
titleAvailability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data
description

WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible individuals by 2025. We have previously reported that use of these medicines is very low, but now aim to assess how such low use relates to their lack of availability or poor affordability.

We analysed information about availability and costs of cardiovascular disease medicines (aspirin, β blockers, angiotensin-converting enzyme inhibitors, and statins) in pharmacies gathered from 596 communities in 18 countries participating in the Prospective Urban Rural Epidemiology (PURE) study. Medicines were considered available if present at the pharmacy when surveyed, and affordable if their combined cost was less than 20% of household capacity-to-pay. We compared results from high-income, upper middle-income, lower middle-income, and low-income countries. Data from India were presented separately given its large, generic pharmaceutical...

subjectMedicine
general
0English
1Elsevier Ltd
210.1016/S0140-6736(15)00469-9
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_S0140_6736_15_00469_9
issn
00140-6736
101406736
21474-547X
31474547X
rsrctypearticle
creationdate2016
addtitleThe Lancet
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
31B1
41P~
51RT
6457
74G.
87-5
99JM
10AABNK
11AAEDT
12AAKOC
13AAQFI
14ABBQC
15ABFNM
16ABLVK
17ABMZM
18ABYKQ
19ACIUM
20ACRLP
21AEKER
22AEVXI
23AFKWA
24AFTJW
25AFXIZ
26AGHFR
27AITUG
28AJBFU
29AJOXV
30AJRQY
31AJUYK
32AMFUW
33AMRAJ
34ANZVX
35BNPGV
36EO8
37EO9
38EP2
39EP3
40FDB
41FIRID
42FNPLU
43G-Q
44GBLVA
45J1W
46KOM
47OD.
48OO~
49P-8
50P-9
51PC.
52R2-
53RPZ
54SAD
55SDF
56SDG
57SEL
58SES
59SSH
60SSZ
61T5K
62UV1
63Z5R
contributorPure Study Investigators (Corporate Author)
startdate20160102
enddate20160102
lsr40The Lancet, 02 January 2016, Vol.387 (10013), pp.61-69
doi10.1016/S0140-6736(15)00469-9
citationpf 61 pt 69 vol 387 issue 10013
lsr30VSR-Enriched:[galeid, pqid]
sort
titleAvailability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data
authorKhatib, Rasha ; Mckee, Martin ; Shannon, Harry ; Chow, Clara ; Rangarajan, Sumathy ; Teo, Koon ; Wei, Li ; Mony, Prem ; Mohan, Viswanathan ; Gupta, Rajeev ; Kumar, Rajesh ; Vijayakumar, Krishnapillai ; Lear, Scott A ; Diaz, Rafael ; Avezum, Alvaro ; Lopez-Jaramillo, Patricio ; Lanas, Fernando ; Yusoff, Khalid ; Ismail, Noorhassim ; Kazmi, Khawar
creationdate20160102
lso0120160102
facets
frbrgroupid8495606556628784602
frbrtype5
newrecords20190904
languageeng
topicMedicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Khatib, Rasha
1Mckee, Martin
2Shannon, Harry
3Chow, Clara
4Rangarajan, Sumathy
5Teo, Koon
6Wei, Li
7Mony, Prem
8Mohan, Viswanathan
9Gupta, Rajeev
10Kumar, Rajesh
11Vijayakumar, Krishnapillai
12Lear, Scott A
13Diaz, Rafael
14Avezum, Alvaro
15Lopez-Jaramillo, Patricio
16Lanas, Fernando
17Yusoff, Khalid
18Ismail, Noorhassim
19Kazmi, Khawar
20Pure Study Investigators
jtitleLancet
creationdate2016
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Khatib
1Mckee
2Shannon
3Chow
4Rangarajan
5Teo
6Wei
7Mony
8Mohan
9Gupta
10Kumar
11Vijayakumar
12Lear
13Diaz
14Avezum
15Lopez-Jaramillo
16Lanas
17Yusoff
18Ismail
19Kazmi
20Pure Study Investigators
aufirst
0Rasha
1Martin
2Harry
3Clara
4Sumathy
5Koon
6Li
7Prem
8Viswanathan
9Rajeev
10Rajesh
11Krishnapillai
12Scott A
13Rafael
14Alvaro
15Patricio
16Fernando
17Khalid
18Noorhassim
19Khawar
auinitR
auinit1R
au
0Khatib, Rasha
1Mckee, Martin
2Shannon, Harry
3Chow, Clara
4Rangarajan, Sumathy
5Teo, Koon
6Wei, Li
7Mony, Prem
8Mohan, Viswanathan
9Gupta, Rajeev
10Kumar, Rajesh
11Vijayakumar, Krishnapillai
12Lear, Scott A
13Diaz, Rafael
14Avezum, Alvaro
15Lopez-Jaramillo, Patricio
16Lanas, Fernando
17Yusoff, Khalid
18Ismail, Noorhassim
19Kazmi, Khawar
addauPure Study Investigators
atitleAvailability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data
jtitleThe Lancet
risdate20160102
volume387
issue10013
spage61
epage69
pages61-69
issn0140-6736
eissn1474-547X
formatjournal
genrearticle
ristypeJOUR
abstract

WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible individuals by 2025. We have previously reported that use of these medicines is very low, but now aim to assess how such low use relates to their lack of availability or poor affordability.

We analysed information about availability and costs of cardiovascular disease medicines (aspirin, β blockers, angiotensin-converting enzyme inhibitors, and statins) in pharmacies gathered from 596 communities in 18 countries participating in the Prospective Urban Rural Epidemiology (PURE) study. Medicines were considered available if present at the pharmacy when surveyed, and affordable if their combined cost was less than 20% of household capacity-to-pay. We compared results from high-income, upper middle-income, lower middle-income, and low-income countries. Data from India were presented separately given its large, generic pharmaceutical...

pubElsevier Ltd
doi10.1016/S0140-6736(15)00469-9
lad01The Lancet
date2016-01-02